Trial · NCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
NCT06247839, Phase 3, Recruiting, Sharmin Ghaznavi
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder. Trials, record NCT06247839. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06247839
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
- NCT number
- NCT06247839
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Sharmin Ghaznavi
- Conditions
- Major Depressive Disorder
- Interventions
- Psilocybin
- First posted
- 2024-02-08
- Last updated
- 2026-08-13
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Massachusetts General Hospital Rumination Questionnaire (MGH-RQ) | Baseline, and 3 weeks, 6 weeks, 9 weeks, and 12 weeks after psilocybin administration. | A transdiagnostic state measure of rumination over the previous two weeks consisting of 9 items on a 5 point Likert scale from 0 (Never/Rarely) to 4 (All The Time). |
| Primary | Change in Resting-State Functional Connectivity | Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration. | Changes in resting-state activity during functional magnetic resonance imaging(fMRI) scans. |
| Primary | Change in Self-Attribution Task performance | Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration. | Participants are shown words one at a time and asked to answer if each of the words apply to 'Self' or 'Other'. |
| Primary | Change in Task-Based Activity during Self-Attribution Task | Baseline, day of psilocybin administration, and 3 weeks, and 12 weeks after psilocybin administration. | Changes in activity in the default mode network during functional magnetic resonance imaging(fMRI) scans while participants perform a self-attribution task. |
| Secondary | Change in Montgomery-Asberg Depression Rating Scale(MADRS) | Baseline, the day before psilocybin administration and at 1 day, 1 week, 2 weeks, 3 weeks, 6 weeks, 9 weeks and 12 weeks after psilocybin administration. | The MADRS is a clinician-rated scale measuring depression severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60; higher scores denote greater severity. |
| Secondary | Change in Quick Inventory of Depressive Symptomatology Self Report - 16 item (QIDS-SR-16) | Baseline, the day before psilocybin administration and at 1 day, 1 week, 2 weeks, 3 weeks, 6 weeks, 9 weeks and 12 weeks after psilocybin administration. | The 16-item QIDS-SR-16 a self-rated scale designed to assess the severity of depressive symptoms in the nine diagnostic symptom domains of a major depressive episodes, exclusive of atypical or melancholic symptoms. The QIDS-SR-16 is sensitive to change with various treatments, demonstrating its utility in research settings. The total score ranges from 0 to 27 with 0 representing no depression and 27 representing severe depression. |
| Secondary | Change in Positive and Negative Affect Schedule (PANAS) | Baseline, the day of psilocybin administration and at 3 weeks and 12 weeks after psilocybin administration. | The PANAS measures the acute emotional drug effects and comprises 2 mood scales that measure positive and negative affect. Participants respond to 20 items using a 5-point scale that ranges from "slightly or not at all (1)" to "extremely (5)". A total higher score on the positive affect questions indicates more of a positive affect while a lower score on the negative affect questions indicates less of a negative affect. |
| Secondary | Change in Structured Interview Guide for the Hamilton Depression Rating Scale with Atypical Depression Supplement (SIGH-ADS) | Baseline and 3 weeks and 12 weeks after psilocybin administration. | The SIGH-ADS is a 25 item scale of the severity of depressive symptoms in terms of Hamilton's 17 item depression scale (score range 0-52) and the addendum of eight atypical symptoms (score range from 0-26). Higher scores are associated with more severe depression symptoms. |
| Secondary | Change in Ruminative Response Scale (RRS) | Baseline and 12 weeks after psilocybin administration. | A self-report measure of describing one's responses to depressed mood, consists of 22 items and three factors (Depression, Brooding, and Reflection). Each item is rated on a 4-point Likert scale ranging from 1 (never) to 4 (always). The total score ranges from 22 to 88, with higher scores indicating higher tendency to ruminate, i.e. higher trait rumination. |
| Secondary | Change in Rumination Reflection Questionnaire (RRQ) | Baseline and 12 weeks after psilocybin administration. | The RRQ measures the extent to which a person tends to ruminate or engage in self-reflection. It consists of 24 items measured on a 5 point Likert scale from 1 (Strongly Disagree) to 5 (Strongly Agree),12 items which assess the tendency to ruminate, and 12 items which assess the tendency to engage in self reflection. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Eriksen Flanker Task | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06247839
GET https://conductscience.org/api/trials/v1/NCT06247839/registered